

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/789,246	02/27/2004	Jeffrey David Bettencourt	03-862-B	9463	
20306 7590 03/30/2007 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606			EXAMINER		
			CORDERO GARCIA, MARCELA M		
			ART UNIT	PAPER NUMBER	
011101100,12			1654		
•					
			MAIL DATE	DELIVERY MODE	
			03/30/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/789,246	BETTENCOURT ET AL.		
Examiner	Art Unit		
Marcela M. Cordero Garcia	1654		

	Marcela M. Cordero Garcia	1654				
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress			
THE REPLY FILED 13 March 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	ving replies: (1) an amendment, aff tice of Appeal (with appeal fee) in (iidavit, or other eviden compliance with 37 Cl	ce, which FR 41.31; or (3)			
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (TWO MONTHS OF THE FINAL REJECTION. See MPEP 76	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN THI 06.07(f).	g date of the final rejection FIRST REPLY WAS F	on. ILED WITHIN			
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropri inally set in the final Office	ate extension fee be action; or (2) as			
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter a Notice of Appeal has been filed, any reply must be filed 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	s of the date of e appeal. Since			
AMENDMENTS 3. ☐ The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	will not be entered by	acause			
(a) ☐ They raise new issues that would require further co (b) ☐ They raise the issue of new matter (see NOTE belo	nsideration and/or search (see NO					
(c) They are not deemed to place the application in bet appeal; and/or			the issues for			
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally rej	ected claims.				
4. The amendments are not in compliance with 37 CFR 1.1.	21. See attached Notice of Non-Co	mpliant Amendment	(PTOL-324).			
5. Applicant's reply has overcome the following rejection(s)	:					
6. Newly proposed or amended claim(s) would be al non-allowable claim(s).						
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the status		II be entered and an e	explanation of			
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected:	•					
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE						
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).	t before or on the date of filing a N d sufficient reasons why the affida	otice of Appeal will <u>no</u> vit or other evidence is	t be entered necessary and			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to c showing a good and sufficient reasons why it is necessar	vercome <u>all</u> rejections under appe	al and/or appellant fai	Is to provide a			
10. The affidavit or other evidence is entered. An explanatio						
REQUEST FOR RECONSIDERATION/OTHER						
11. The request for reconsideration has been considered bu	t does NOT place the application i	n condition for allowar	nce because:			
 12. ☐ Note the attached Information Disclosure Statement(s). 13. ☒ Other: See Continuation Sheet. 	(PTO/SB/08) Paper No(s).	M M	Merlea_			
	ANISH GUPTA PRIMARY EXAMINER	Marcela M Cordero Patent Examiner Art Unit 1654	Garcia, PhD			

Continuation of 11.

Continuation of 13. Other: does NOT place the application in condition for allowance because: Applicant argues that there is no teaching, motivation or suggestion in Sporeno for removing contaminants before the metal chelating steps or that a heparin column is desirable for removing contaminants. In addition, Sporeno's methods results in a cytokine preparation that is more than 95% pure and fully active, requiring no further purification, and that the combination of the references is improper hindsight. Accordingly, one skilled in the art would derive no motivation whatosever from Sporeno to combine with the method of Newton. Applicant's arguments regarding the 103 rejection of record have been carefully considered but not deemed persuasive because of the reasons of record and because both Sporeno and Newton teach polyhistidine tagged protein purification, because cytokines are proteins and because further purifying a product, even if it at 95% purity, would be desirable for many reasons, e.g., to minimize secondary reactions, for therapeutic uses, in vitro studies, and so forth, even if Sporeno is silent with respect to such desirability.